Genmab A (GMAB) Profit After Tax (2018 - 2026)
Genmab A's (GMAB) quarterly Profit After Tax came in at $53.0 million in Q1 2026, down 72.82% YoY from $195.0 million in Q1 2025, and down 94.31% on a QoQ basis from $932.0 million in Q3 2025.
Genmab A (GMAB) Profit After Tax (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Profit After Tax data on file, last reported at $53.0 million in Q1 2026.
- Quarterly Profit After Tax fell 72.82% year-over-year to $53.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 25.53% YoY) and the FY2025 annual result came in at $963.0 million, down 15.0% from the prior year.
- Profit After Tax eased to $53.0 million in Q1 2026, from $932.0 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $932.0 million in Q3 2025 to a low of $53.0 million in Q1 2026.
- A 3-year average of $411.3 million and a median of $395.0 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2025 — Profit After Tax soared 60.41% — and 2026, when it tumbled 72.82%.
- Tracing GMAB's Profit After Tax over 3 years: stood at $581.0 million in 2024, then soared by 60.41% to $932.0 million in 2025, then slumped by 94.31% to $53.0 million in 2026.
- The last three Profit After Tax figures came in at $53.0 million (Q1 2026), $932.0 million (Q3 2025), and $531.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 303.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 303.00 Mn |
| Mar 31, 2026 | 53.00 Mn |
| Sep 30, 2025 | 932.00 Mn |
| Jun 30, 2025 | 531.00 Mn |
| Mar 31, 2025 | 195.00 Mn |
| Sep 30, 2024 | 581.00 Mn |
| Jun 30, 2024 | 395.00 Mn |
| Mar 31, 2024 | 192.00 Mn |
| Sep 30, 2020 | 530.00 |
| Dec 31, 2019 | 537.00 |
| Sep 30, 2019 | 537.05 Mn |
| Dec 31, 2018 | 179.18 Mn |